HK Stock Market Move | NEW GONOW RV (00805) rose nearly 8% in morning trading to a new high; ten departments jointly introduced measures to boost RV consumption.
NEW GONOW RV (00805) rose nearly 8% in morning trading, hitting a high of HK$12, a record high. As of press time, it was up 6.10% at HK$11.82, with a turnover of HK$129 million.
NEW GONOW RV (00805) rose nearly 8% in morning trading, hitting a high of HK$12, a record high. As of press time, it was up 6.10% at HK$11.82, with a turnover of HK$129 million.
On the news front, on September 18, the General Office of the State Council forwarded the "Several Measures on Promoting RV Consumption" issued by ten departments including the Ministry of Culture and Tourism, systematically clearing bottlenecks in RV consumption across seven areas: improving the quality of RV supply, optimizing RV registration and scrapping management, ensuring RV passage and parking, strengthening RV campsite construction, improving RV rental services, and increasing financial support.
Public information shows that NEW GONOW RV owns three major brands: the mid-range brand SNOWY RIVER, the high-end brand REGENT, and the light off-road brand NEWGEN, and holds a leading market share in Australia and New Zealand. According to 2023 data, New Gonow's market share in the Australia-New Zealand RV market reached 7.8%, ranking second.
Related Articles

Jiangsu Hengrui Pharmaceuticals (600276.SH) signed a licensing agreement with Novo Nordisk A/S for the HRS-1596 project.

HARBIN BANK (06138) Enhances and Expands Agricultural Services to Support High-Quality Development of Agriculture in Heilongjiang

Jiangsu Hengrui Pharmaceuticals (01276) licenses exclusive overseas rights to HRS-1596 to Novo, with a potential transaction value of up to US$2.6 billion.
Jiangsu Hengrui Pharmaceuticals (600276.SH) signed a licensing agreement with Novo Nordisk A/S for the HRS-1596 project.

HARBIN BANK (06138) Enhances and Expands Agricultural Services to Support High-Quality Development of Agriculture in Heilongjiang

Jiangsu Hengrui Pharmaceuticals (01276) licenses exclusive overseas rights to HRS-1596 to Novo, with a potential transaction value of up to US$2.6 billion.






